Durex-Maker Reckitt Avoids $20 Billion Headache

Turning down Pfizer’s $20 billion consumer-health business shows discipline, but leaves U.K. giant Reckitt Benckiser with plenty of work.

from WSJ.com: US Business http://ift.tt/2G2T7YA
via IFTTT